Kevin Waters - 13 Aug 2026 Form 4 Insider Report for PROCEPT BioRobotics Corp (PRCT)

Reporting relationship: EVP, CFO
Issuer ticker: PRCT
Reported as of: 13 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2026, 16:34:40 UTC
Prior SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Stone, Attorney-in-Fact for Kevin Waters

Key filing fact

Kevin Waters filed Form 4 for PROCEPT BioRobotics Corp (PRCT) on 14 Aug 2026.

Key facts

This page summarizes Kevin Waters's Form 4 filing for PROCEPT BioRobotics Corp (PRCT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Aug 2026, 16:34.

Change

Previous filing in this sequence was filed on 10 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001653771 Primary reporting owner

Waters Kevin

Relationship: EVP, CFO
Address: C/O PROCEPT BIOROBOTICS CORPORATION, 150 BAYTECH DRIVE, SAN JOSE
Signature: /s/ Jonathan Stone, Attorney-in-Fact for Kevin Waters
Signature date: 14 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRCT transaction

Common Stock

Award

Transaction value
Shares: +29,527
Change %: +20%
Price: $0.000000^*
Shares after: 180,728
Date: 13 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRCT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +40,851
Change %
Price: $0.000000^*
Shares after: 40,851
Date: 13 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,851
Exercise price: $21.95
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-quarter of the RSUs shall vest on August 13, 2027, with one-sixteenth of the remaining RSUs vesting quarterly over 36 months, subject to the Reporting Person continuing as a service provider through such date. The grant is intended to be 50% of the value of the Reporting Person's expected 2027 grant, and made in lieu of such portion of the expected 2027 grant.

Footnote F2

1/48th of the shares subject to the Stock Option shall vest monthly from the vesting commencement date of August 13, 2026, over a four year period, subject continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. The grant is intended to be 50% of the value of the Reporting Person's expected 2027 grant, and made in lieu of such portion of the expected 2027 grant.